Aim: Omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported to reduce the risk of cardiovascular disease. However, whether omega-3 PUFAs are involved in the pathogenesis of abdominal aortic aneurysms (AAA) remains unclear. Methods: We analyzed 67 consecutive patients admitted for the elective surgical repair of AAA. We investigated the association of serum EPA and DHA levels as well as the EPA/AA ratio with the size of AAA assessed using three-dimensional reconstructed computed tomography images. Results: Mean patient age was 70 9 years and 60 patients were male. Serum EPA and DHA levels were 75.2 35.7 µg/mL and 146.1 48.5 µg/mL, respectively. EPA/AA ratio was 0.44 0.22, which was lower than those in healthy Japanese subject and equivalent to those in Japanese patients with coronary artery disease as previously reported. Mean of the maximum AAA diameter was 56.4 8.9 mm, and serum EPA levels and EPA/AA ratio negatively correlated with it (r 0.32 and r 0.32, respectively). Multiple liner regression analysis showed that EPA levels were significant independent factor contributing to the maximum AAA diameter. Furthermore, low serum EPA levels and low EPA/AA ratio were significantly associated with the growth rate of AAA diameter (r 0.43 and r 0.33, respectively). Conclusion: EPA levels in patients with AAA were relatively low. Low serum EPA levels and EPA/AA ratio were associated with the size and growth rate of AAA.
Introduction
Dietary intake of fish-derived omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been recommended to reduce the risk of cardiovascular disease [1] [2] [3] [4] . Omega-3 PUFAs have been demonstrated to Copyright©2017 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
Methods

Study Subjects
We enrolled 86 consecutive patients who were admitted to Juntendo University Hospital for the purpose of treatment for AAA by elective Endovascular Aneurysm Repair (EVAR) and conventional surgical repair from January 2013 to June 2016. We measured serum concentrations of PUFAs [EPA, DHA, and arachidonic acid (AA)] on admission. Eleven patients were excluded because 1 patient had an infected aneurysm, 1 patient had an endoleak after previous EVAR, 7 patients had taken pure EPA and 2 patients had received hemodialysis. Eight patients had not undergone three-dimensional (3D) reconstructed computed tomographic (CT) scan imaging before surgery. Finally, we analyzed 67 patients. We investigated whether serum omega-3 PUFAs (EPA and DHA), AA and the EPA/AA ratio are associated with the size of AAA. All subjects provided informed consent, the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and the study was approved by the ethical committee of Juntendo University Hospital.
Blood pressure (BP) was measured using a standard mercury sphygmomanometer. Height and weight were measured using an automated scale, and body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or currently taking antihypertensive medications. Dyslipidemia was defined as a low-density lipoprotein cholesterol (LDL-C) level ≥ 140 mg/dL, a high-density lipoprotein cholesterol (HDL-C) level 40 mg/dL, a triglycerides (TG) level ≥ 150 mg/dL, or currently taking lipid-lowering medications. Diabetes mellitus (DM) was defined as a documented history of diabetes treated with medications or hemoglobin A1c (HbA1c) of National Glycohemoglobin Standardization Program (NGSP) level ≥ 6.5%, fasting plasma glucose level ≥ 126 mg/dL, or non-fasting plasma glucose level ≥ 200 mg/dL.
Blood Sampling
Whole blood samples were drawn after overnight fasting within 24 h of admission. Serum levels of total cholesterol (TC), TG, and HDL-C were measured using standard enzymatic methods, and LDL-C values were calculated using the Friedewald formula 13) . Plasma glucose concentrations and HbA1c, C-reactive protein (CRP), and creatinine (Cr) levels were measured using standardized methods. The estimated glomerular filtration rate was calculated based on the Jap- 14) . Serum concentrations of EPA, DHA, and AA levels were measured by SRL Inc. (Tokyo, Japan) using standard laboratory protocols.
Computed Tomography, Measuring Aneurysm Diameter
All 67 patients had undergone 3D reconstructed CT scan imaging before surgery. All CT angiographies were performed on a multidetector row CT scanner with 64 detectors (Aquilion; Toshiba, Tokyo, Japan). These CT images were reviewed on a 3D workstation (Synapse Vincent; Fujifilm, Tokyo, Japan). The aneurysm's maximum diameter was evaluated, with measurements obtained perpendicular to the centerline of aorta and aneurysm 15, 16) . The centerline of aorta and aneurysm was identified, and a curved multiplanar reconstruction (CPR) image was created. Then, the maximum diameter on CPR was determined using the cross section perpendicular to the centerline in this CPR image 17) . Representative images used to determine the maximum diameter of AAA are shown in Fig. 1 .
Coronary Artery Disease
CAD was defined as patients with a documented history of acute myocardial infarction, coronary artery bypass graft surgery, or documented presence of significant coronary artery stenosis (luminal narrowing ≥ 50%) in at least one major coronary artery by coronary angiography or multidetector computed tomographic angiography 18, 19) . Coronary angiography was performed according to standard methods 20) . Coronary segments were analyzed according to the model of the American College of Cardiology/American Heart Association 21) .
Statistical Analysis
Continuous variables were expressed as mean standard deviation (SD), and categorical variables were reported as percentages. Statistical differences between the groups were analyzed by unpaired Student's t-test, the chi-square test, Fisher's exact test, or the Mann-Whitney-Wilcoxon rank-sum test, as appropriate. Correlations between 2 variables were determined by simple linear regression analysis. Spearman correlations were used when variables were not normally distributed. Multiple linear regression analysis was used to determine the factors independently contributing to the maximum AAA diameter among the variables with a P value 0.1 in univariate analysis (BMI, EPA and using blocker). All statistical analyses were performed using JMP 12 software for Windows (SAS Institute, Cary, NC, USA.). Statistical significance was defined as a P-value 0.05.
Results
Clinical Characteristics of Patients
The baseline characteristics of all patients are shown in Table 1 . Over all 67 patients, the mean age was 70 9 years, BMI was 24.8 2.9 kg/m 2 , and 60 (89.6%) were male. Nineteen (28.4%) patients had a history of current smoking. The number of hypertension, dyslipidemia, diabetes mellitus, and coronary artery disease patients were 52 (77.6%), 59 (88.1%), 13 (19.4%), and 40 (59.7%), respectively.
Serum PUFA Levels in Patients with AAA
As shown in Table 1 , serum levels of EPA, DHA, and AA were 75.2 35.7, 146.1 48.5, and 184.3 53.7 µg/mL, respectively. The EPA/AA ratio was 0.44 0.22, and the median value was 0.41. We have previously reported serum levels of PUFAs in a healthy Japanese population living in an urban area. In subjects aged over 65 years, serum levels of EPA, DHA, and AA were 81.9 31.1, 123.2 27.0, and 119.8 22.7 µg/mL, respectively. The EPA/AA ratio was 0.68 0.22 22) . Therefore, serum levels of EPA had a tendency to decrease with age, those of DHA, and AA had a tendency to increase with age, and the EPA/AA ratio was also relatively lower than in healthy Japanese subjects.
Correlations between Serum PUFA Levels and AAA Diameter
Mean of the maximum AAA diameter was 56.4
8.9 mm. There were no significant correlations between maximum AAA diameter and conventional risk factors (e.g., hypertension, dyslipidemia, diabetes mellitus, current smoking, and coronary artery disease). There were no significant correlations between serum levels of TC, HDL-C, LDL-C, TG, HbA1c, creatinine and CRP, and maximum AAA diameter. Although statins, blockers, and angiotensin pathway inhibition (angiotensin converting enzyme inhibitors or angiotensin receptor blockers) were pharmacological treatment strategy for AAA, only blocker usage was associated with AAA diameter ( Table 2) .
As shown in Fig. 2 , serum levels of EPA and the EPA/AA ratio were negatively correlated with maximum AAA diameter (r 0.32, P 0.0073, and r 0.32, P 0.0075, respectively). However, there were no significant correlations between maximum AAA diameter and serum levels of DHA and AA. Multiple liner regression analysis showed that serum levels of EPA were significant independent factor contributing to maximum AAA diameter (EPA: 0.269, P 0.02, BMI: 0.125, P 0.2, using blocker: 0.109, P 0.3) ( Table 3) .
Comparison between Serum PUFA Levels between the CAD and the Non-CAD Groups
The patients were also divided into a CAD group and a non-CAD group. Characteristics of the patients in both groups are shown in Table 1 . The EPA/AA ratio was not significantly different between the two groups (0.43 0.22 vs. 0.45 0.23, P 0.72). Serum levels of EPA in the non-CAD group tended to correlate with maximum AAA diameter (r 0.38, P 0.050), and the EPA/AA ratio in the non-CAD group was negatively correlated with maximum AAA The centerline of the aorta and aneurysm is identified and curved multiplanar reconstruction (CPR) images are created (A, B and C). Then, the maximum diameter is determined using the cross section perpendicular to the centerline in the CPR image (D). diameter (r 0.42, P 0.030). Whereas maximum AAA diameter tended to be associated with both serum levels of EPA and the EPA/AA ratio (r 0.26, P 0.10, and r 0.28, P 0.079, respectively) in the CAD group (Fig. 3) .
Correlations between Serum PUFA Levels and Growth Rate of AAA Diameter
We investigated the rate of AAA expansion.
Among all study subjects, for 41 patients previously performed CT scans over at least six-month intervals could be reviewed retrospectively. We evaluated aneurysms by measuring the traditional maximum minoraxis diameter using the cross sectional slice. Mean of the maximum minor-axis AAA diameter was 48.8 6.1 mm. Mean follow-up time was 30.6 22.5 months (range 6-77 months). The mean monthly growth rate of maximum minor-axis AAA diameter was 0.28 0.12 mm/month (range 0.11-0.64 mm). Systolic blood pressure and diastolic blood pressure were positively correlated with monthly growth rate of maximum minor-axis AAA diameter (r 0.39, P 0.0097, and r 0.31, P 0.045, respectively) and serum levels of creatinine was negatively correlated with monthly growth rate of maximum minor-axis AAA diameter (r 0.33, P 0.035). Serum levels of EPA and the EPA/AA ratio were negatively correlated with AAA growth rate (r 0.43, P 0.0056, and r 0.33, P 0.033, respectively), as shown in Fig. 4 . regression analysis was performed among variables with a P value 0.1 in univariate analysis (BMI, EPA and using blocker). Using blocker was assigned a value of 1. Non using blocker was assigned a value of 0. 
Discussion
To our knowledge, this is the first study to assess the association between serum levels of PUFAs and the development of AAA in a clinical setting. In patients with AAA, serum levels of EPA had a tendency to decrease with age, DHA, and AA, had a tendency to increase with age, and the EPA/AA ratio was also relatively lower than in healthy Japanese subject 22) . Moreover, there were significant negative correlations between serum levels of EPA and the EPA/AA ratio and maximum AAA diameter and growth rate of AAA diameter.
Compared with our previous report of serum PUFA levels in healthy Japanese subjects 22) , patients with AAA showed low EPA levels and EPA/AA ratios. Several previous studies have demonstrated that serum levels of EPA and EPA/AA ratios in patients with CAD are lower than those in normal subjects. The JELIS study showed that the average ratio of EPA/AA serum levels was 0.6 in the primary and secondary prevention study 2, 23) . In the Tochigi Ryoma EPA/AA Trial in Coronary Artery Disease (TREAT-CAD), the EPA/AA ratio was measured in 428 patients who underwent diagnostic coronary angiography because they were suspected to have CAD. The average EPA/ AA ratio was 0.49, and its median value was 0.37 24) . We also evaluated serum PUFA levels in patients with acute coronary syndrome in a metropolitan area in Japan. The EPA/AA ratio was 0.46 in 72 patients 25) . The EPA/AA ratio of serum levels in our study subjects was 0.44 0.22, which is equivalent to previous reports in patients with CAD. In addition, serum levels of EPA and the EPA/AA ratio in patients with AAA in the non-CAD group were equivalent to those, in the CAD group, suggesting that serum levels of EPA, and the EPA/AA ratio in patients with AAA is relatively low regardless of the presence of CAD.
Serum levels of EPA and the EPA/AA ratio were significantly negatively correlated with maximum AAA diameter and the growth rate of AAA. AAA formation is associated with chronic aortic wall inflammation, which is linked to the production of elastinand collagen-degrading enzymes such as matrix metalloproteinases (MMP)-2 and MMP-9 26, 27) . We have reported that, in the AAA model that was developed by angiotensin infusion in apolipoprotein E-deficient mice, administration of both EPA and DHA suppressed the infiltration of macrophages and that down-regulation of inflammatory cytokines and enzymes in the aortic wall resulted in inhibition of the development of AAA 12) . Wang et al. have also demonstrated that an EPA-rich diet can attenuate AAA formation in a murine CaCl2-induced AAA model by suppressing tissue remodeling 28) . These results from in vivo studies could account for the association between lower EPA and EPA/AA ratio and the severity of AAA.
Although DHA as well as EPA has been recommended to reduce the risk of cardiovascular disease, Yagi et al. reported that the serum levels of DHA, but not EPA, are associated with the endothelial function in patients with CAD 29) . Furthermore, we have reported that both EPA and DHA inhibited the development of AAA in a mouse model 12) . However, serum DHA levels did not correlate with AAA formation in our study population. The mechanism(s) by which only EPA levels were associated with AAA formation is unclear. Therefore, further studies will be required to clarify the different role between DHA and EPA in the pathogenesis of AAA.
Conventional risk factors for AAA are advanced age, male gender, smoking, hypertension, dyslipidemia, and CAD. Pharmacological treatment strategies for AAA are statins, blockers, and angiotensin pathway inhibition. Several cohort studies have implicated that statins are associated with lower AAA growth rates 30, 31) . In this study, the CAD group tended to have more conventional risk factors than the non-CAD group, and the CAD group tended to use more pharmacological treatment for AAA than the non-CAD group, especially statins and blockers. There were stronger correlations of serum levels of EPA and EPA/AA ratio with maximum AAA diameter in the non-CAD group than in the CAD group. These results suggest that low serum levels of EPA and a low EPA/AA ratio contribute more to the development of AAA in patients with fewer conventional risk factors.
This study has several limitations. Firstly, this study was a cross-sectional survey. Therefore, we could not show the causal relationship between PUFA levels and the development of AAA. Secondly, the study sample size was relatively small. Although this study showed a significant correlation between EPA and AAA, a larger prospective study is needed to confirm our results.
Conclusion
The EPA level and EPA/AA ratio may be relatively lower in patients with AAA than in healthy Japanese subjects and equivalent to those in patients with CAD previously reported. Low levels of serum EPA and a low EPA/AA ratio are associated with the severity of AAA. Further investigation would be required to assess whether low serum levels of EPA and a low EPA/AA ratio are potential therapeutic targets.
